Market Opportunity Target urology clinics and hospital systems treating BPH with LUTS, emphasizing Aquablation therapy as size and shape independent and less operator dependent to reduce procedure variability and improve durable outcomes.

Clinical Evidence Leverage the extensive peer‑reviewed evidence base of over 150 publications to support value propositions, drive clinician adoption, and bolster payer negotiations around long-term efficacy and safety.

Regulatory Footprint Prioritize expansion and upsell in regions where HYDROS robotic system is cleared (US, EU, UK) while preparing tailored training and installation plans to overcome adoption frictions in new markets.

Revenue Levers Monitor and address inventory management and single‑use handpiece demand, offering bundled caps and service plans to stabilize sales cadence and mitigate quarterly declines observed in supply components.

Competitive Positioning Differentiate with AI‑powered robotics, durable clinical outcomes, and operator‑friendly workflow to win large hospital alliances and procurements against peers in surgical robotics for urology.